BHWM
HRTX icon

Beaird Harris Wealth Management’s Heron Therapeutics HRTX Stock Holding History

Beaird Harris Wealth Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-148
Closed -$153 – 614
2023
Q3 		$153 Hold
148
– – ﹤0.01% 433
2023
Q2 		$172 Hold
148
– – ﹤0.01% 440
2023
Q1 		$224 Hold
148
– – ﹤0.01% 456
2022
Q4 		$370 Sell
148
-52
-26% -$168 ﹤0.01% 712
2022
Q3 		$1K Hold
200
– – ﹤0.01% 437
2022
Q2 		$1K Hold
200
– – ﹤0.01% 373
2022
Q1 		$1K Hold
200
– – ﹤0.01% 562
2021
Q4 		$2K Buy
+200
New +$2.04K ﹤0.01% 569

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Beaird Harris Wealth Management's HRTX Position: Q4 2023 in Review

Beaird Harris Wealth Management sold out of Heron Therapeutics (HRTX) in Q4 2023, closing a stake of 148 shares — an estimated $153 sold.

Beaird Harris Wealth Management first reported a position in HRTX in Q4 2021 and held it in 8 quarters. The position peaked at $2K in Q4 2021. 151 funds tracked by Wall St. Rank hold HRTX as of Q4 2023.

  • Beaird Harris Wealth Management reported no remaining Heron Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Beaird Harris Wealth Management sold 148 Heron Therapeutics shares in Q4 2023, an estimated $153.
  • Beaird Harris Wealth Management first reported a position in Heron Therapeutics in Q4 2021 and held it in 8 quarters.
  • Beaird Harris Wealth Management's Heron Therapeutics position peaked at $2K in Q4 2021.
  • 151 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2023.

Based on Beaird Harris Wealth Management's 13F filing for Q4 2023, filed 27 Feb 2024.